

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

Data Sheet (Cat.No.T16409)



OSMI-1

Chemical Propert	ies
CAS No. :	1681056-61-0
Formula:	C28H25N3O6S2
Molecular Weight:	563.64
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year

Biological Description

Description	OSMI-1 is an O-GlcNAc transferase (OGT) inhibitor (IC50=2.7 µM) that is orally active and cell-permeable. OSMI-1 inhibits protein O-GlcNA acetylation without qualitatively altering cell-surface N- or O- linked glycans.
Targets(IC50)	Others,Acyltransferase
In vitro	 METHODS: COS7 and Hela cells were treated with OSMI-1 (2-100 μM) for 24 h. Cell viability was measured using the CCK8 Assay. RESULTS: 50 μM OSMI-1 reduced cell viability by more than 50%. [1] METHODS: CHO cells were treated with OSMI-1 (10-100 μM) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: OSMI-1 reduced global OGlcNAcylation in a dose-dependent manner, with a maximum effect at 50 μM. [2]
In vivo	 METHODS: To assay antitumor activity in vivo, OSMI-1 (1 mg/kg, i.v.) and TRAIL (500 µg/kg, intraperitoneally) were administered to BALB/c-Foxn1nu/ArcGem nude mice harboring human colorectal carcinoma tumor HCT116 once daily for three weeks. RESULTS: Tumor size was slightly reduced in mice treated with OSMI-1 or TRAIL alone, but significantly reduced in the OSMI-1 and TRAIL combination group. The combination treatment synergistically increased the antitumor activity of transplanted tumors in HCT116 nude mice. [3] METHODS: To investigate the protective effect against Stx-mediated pathogenic responses, OSMI-1 (300-1000 µg/mouse in water containing 4.5% DMSO and 5% Tween 80) was injected intraperitoneally into Stx2a-attacked C57BL/6 mice once daily for sever days. RESULTS: O-GlcNAc inhibition ameliorated the mortality and various disease symptoms induced by Stx2a exposure in mice, which was further enhanced by O-GlcNAc inhibition [4]

Solubility Information			
Solubility	DMSO: 18.33 mg/mL (32.53 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)		

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg		
1 mM	1.7742 mL	8.8709 mL	17.7418 mL		
5 mM	0.3548 mL	1.7742 mL	3.5484 mL		
10 mM	0.1774 mL	0.8871 mL	1.7742 mL		
50 mM	0.0355 mL	0.1774 mL	0.3548 mL		

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Wang N, Yu M, Fu Y, et al. Blocking ATM Attenuates SKOV3 Cell Proliferation and Migration by Disturbing OGT/OGA Expression via hsa-miR-542-5p. Frontiers in Oncology. 2022.12
br/>Liu Y, et al. Discovery of a Low Toxicity O-

Inhibitor • Natural Compounds • Compound Libraries • Recombinant Proteins This product is for Research Use Only• Not for Human or Veterinary or Therapeutic Use Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481